Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study-Reference-Cited by-同舟云学术

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Published:2013-11 Issue:11 Volume:3 Page:e162-e162
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Offidani M,Corvatta L,Maracci L,Liberati A M,Ballanti S,Attolico I,Caraffa P,Alesiani F,Caravita di Toritto T,Gentili S,Tosi P,Brunori M,Derudas D,Ledda A,Gozzetti A,Cellini C,Malerba L,Mele A,Andriani A,Galimberti S,Mondello P,Pulini S,Coppetelli U,Fraticelli P,Olivieri A,Leoni P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201358.pdf

Reference59 articles.

1. Jakubowiak A . Management strategies for relapsed/refractory multiple myeloma. Semin Hematol 2012; 49 (Suppl 1): S16–S32.

2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

3. Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012; 17: 592–606.

4. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M . Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia 2012; 26: 73–85.

5. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

2. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

3. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice;Cancers;2023-04-05

4. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse;Current Oncology;2023-02-15

5. Cancers of the Blood;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13